The mAb NEO-201 with selective CEACAM5 and CEACAM6 targeting capacity and anti-tumour activity showed strong immunoreactivity in a cohort of MOC samples and other tumour types with minimal cross-reactivity to surrounding normal tissue [108]. The gene discussed is CEACAM5; the disease is neoplasm.